Efficacy of epiroprim (Ro11-8958), a new dihydrofolate reductase inhibitor, in the treatment of acute Toxoplasma infection in mice

American Journal of Tropical Medicine and Hygiene

Volumn 54, Issue 3, 1996, Pages 249-252

  Martinez, Anthony ^a,b   Allegra, Carmen J ^a,c   Kovacs, Joseph A ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b ST AGNES HOSPITAL   (United States)

^c NATIONAL NAVAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TOXOPLASMA; TOXOPLASMA GONDII;

ANTIINFECTIVE AGENT; ANTIPROTOZOAL AGENT; DAPSONE; DRUG DERIVATIVE; EPIROPRIM; FOLIC ACID ANTAGONIST; SULFADIAZINE; TRIMETHOPRIM; DIHYDROFOLATE REDUCTASE INHIBITOR; PYRIMETHAMINE;

ACUTE DISEASE; ANIMAL; ANIMAL PARASITOSIS; ARTICLE; BAGG ALBINO MOUSE; DRUG COMBINATION; HALF LIFE TIME; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; ORAL DRUG ADMINISTRATION; SUBCUTANEOUS DRUG ADMINISTRATION; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL CELL; ANIMAL MODEL; DRUG EFFICACY; ENZYME INHIBITION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; OPPORTUNISTIC INFECTION; TOXOPLASMA GONDII; TOXOPLASMOSIS;

ACUTE DISEASE; ADMINISTRATION, ORAL; ANIMALS; ANTI-INFECTIVE AGENTS; ANTIPROTOZOAL AGENTS; DAPSONE; DRUG THERAPY, COMBINATION; FOLIC ACID ANTAGONISTS; HALF-LIFE; HUMANS; INJECTIONS, INTRAPERITONEAL; INJECTIONS, SUBCUTANEOUS; MICE; MICE, INBRED BALB C; SULFADIAZINE; TOXOPLASMOSIS, ANIMAL; TRIMETHOPRIM;

EID: 0029664510     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.1996.54.249     Document Type: Article

References (13)

1. Haverkos HW, 1987. Assessment of therapy for toxoplasma encephalitis: the TE study group. Am J Med 82: 907-914.
2. Leport C, Raffi F, Matheron S, Katlama C, Regnier B, Saimot AG, Marche C, Vedrenne C, Vilde JL, 1988. Treatment of central nervous system toxoplasmosis with pyrimethamine/ sulfadiazine combination in 35 patients with the acquired immunodeficiency syndrome. Efficacy of long-term continuous therapy. Am J Med 84: 94-100.
3. Dannemann BR, McCutchan JA, Israelski DM, Antonioskis D, Leporte C, Luft BJ, Nussbaum JM, Clumeck N, Morlat P, Chiu J, Vilde J-L, Orellana M, Feigal D, Bartok J, Heseltine P, Leedom J, Remington J, 1992. Treatment of toxoplasmic encephalitis in patients with AIDS: a randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. Ann Intern Med 116: 33-43.
4. Chang HR, Pechere J-CF, 1988. In vitro effects of four macrolides (roxithromycin, spiramycin, azithromycin, and A-56268) on Toxoplasma gondii. Antimicrob Agents Chemother 32: 524-529.
5. Fernandez-Martin J, Leport C, Morlat P, Meyohas M-C, Chauvin J-P, Vilde J-L, 1991. Pyrimethamine-clarithromycin combination for therapy of acute Toxoplasma encephalitis in patients with AIDS. Antimicrob Agents Chemother 35: 2049-2052.
6. Hagberg L, Palmertz B, Lindberg J, 1993. Doxycycline and pyrimethamine for toxoplasmic encephalitis. Scand J Infect Dis 25: 157-160.
7. Walzer PD, Foy J, Steele P, White M, 1993. Synergistic combinations of Ro11-8958 and other dihydrofolate reductase inhibitors with sulfamethoxazole and dapsone for therapy of pneumocystosis. Antimicrob Agents Chemother 37: 436-443.
8. Kovacs JA, Allegra CJ, Chabner BA, Swan JC, Drake J, Lunde M, Parrillo JE, Masur H, 1987 Potent effect of trimetrexate, a lipid-soluble antifolate, on Toxoplasma gondii. J Infect Dis 155: 1027-1032.
9. Allegra CJ, Kovacs JA, Drake JC, Swan JC, Chabner BA, Masur H, 1987. Activity of antifolates against Pneumocystis carinii dihydrofolate reductase and identification of a potent new agent. J Exp Med 165: 926-931.
10. Then RL, Hartman PG, Kompis I, Santi DV, 1993. Selective inhibition of dihydrofolate reductase from problem human pathogens. Adv Exp Med Biol 338: 533-536.
11. Allegra CJ, Kovacs JA, Drake JC, Swan JC, Chabner BA, Masur H, 1987. Potent in vitro and in vivo anti-Toxoplasma activity of the lipid-soluble antifolate trimetrexate. J Clin Invest 79: 478-482.
12. Chang HN, Arsenijevic D, Comte R, Polak A, Then RL, Pechere J-C, 1994. Activity of epiroprim (Ro11-8958), a dihydrofolate reductase inhibitor, alone and in combination with dapsone against Toxoplasma gondii. Antimicrob Agents Chemother 38: 1803-1807.
13. Cavallito JC, Nichol CA, Brenckman WD, DeAngelis RL, Stickney DR, Simmons WS, Sigel CW, 1978. Lipid-soluble inhibitors of dihydrofolate reductase I. Kinetics, tissue distribution, and extent of metabolism of pyrimethamine, metroprine and etoprine in the rat, dog and man. Drug Metab Dispos 6: 329-337.